The steep discount between trailing and forward P/E suggests investors are pricing in a normalization of earnings power as potash and bromine prices recover. The EV/EBITDA of 7.3x is in line with Nutrien's 7.2x, but the forward EV/EBITDA of 4.8x is below the peer group, indicating the market may still be applying a geopolitical discount. The PEG of 0.54, based on forward growth estimates, suggests the stock is inexpensive relative to its expected earnings growth, but this hinges on the sustainability of the cyclical upswing.

The stability of gross margin around 31% suggests ICL retains pricing power in its specialty segments, but the thin net margin of 6.4% reflects heavy royalties, taxes, and interest expenses that compress profitability. Operating margin improved to 12.5% in 2026Q2 from 5.8% in 2025Q4, showing operating leverage, yet net margin remains below the 8.4% reported by Nutrien, highlighting the structural cost disadvantages of the Israeli tax and royalty regime. Investors should monitor whether the shift toward specialty products can lift net margins toward the mid-teens, as seen in specialty chemical peers.

Despite a low-cost extraction advantage, ROIC of 2.2% in 2026Q2 is barely above the risk-free rate, suggesting that heavy capital investment in mining infrastructure and the Polysulphate project is not yet yielding adequate returns. ROE of 2.1% is similarly depressed, reflecting the combination of thin net margins and a conservative balance sheet. The gap between ROIC and the cost of capital implies that value creation is limited, and any improvement will depend on margin expansion rather than asset efficiency, as asset turnover has remained flat at 0.16x.

The CCC of 114 days is driven by DIO of 114 days, reflecting the need to hold large inventories of potash and phosphate products, and DSO of 70 days, which is high relative to peers. The slight improvement from 140 days in 2025Q4 is encouraging, but the trend over the past year shows persistent working capital intensity. This suggests that ICL's operational efficiency is constrained by the nature of its bulk commodity business, and any further deterioration in collection or inventory turnover could pressure free cash flow.

The increase in leverage is driven by a $0.5B rise in total debt to $3.3B, likely to fund capex and acquisitions, as evidenced by the goodwill spike. Interest coverage of 2.7x is down from 9.9x in 2024Q4, reflecting both higher debt and lower operating income in the interim. However, the D/E of 0.51 is in line with Nutrien's 0.51 and below CF Industries' 0.51, suggesting ICL is not over-levered relative to peers. The low absolute debt level and strong cash generation provide a cushion, but investors should monitor the trajectory of coverage if earnings remain depressed.

The quick ratio of 0.94 indicates that ICL relies on inventory to meet short-term obligations, which is typical for a commodity producer but could be a vulnerability if inventory values decline. The improvement in the current ratio is partly due to a reduction in current liabilities, but the absolute cash balance remains modest relative to the company's size. Given the geopolitical risks and potential shipping disruptions, the liquidity position appears adequate but not robust, and a prolonged disruption could strain working capital.

On EV/EBITDA, ICL trades at 7.3x, in line with Nutrien, but its ROE of 3.7% is far below Nutrien's 9.5% and CF Industries' 25.7%, indicating lower profitability. The P/B of 1.15x is below Nutrien's 1.31x but above Mosaic's 0.56x, reflecting the market's view of asset quality. The discount may be justified by the higher political risk and the 2030 concession expiry, but if ICL can demonstrate improved returns, the valuation gap could narrow. Investors should compare ICL to specialty chemical peers like Albemarle, which trade at higher multiples, to assess whether the market is undervaluing the bromine franchise.